Oasmia Pharmaceutical AB
Year-end report for the fiscal year May 2014 – April 2015
DGAP-News: Oasmia Pharmaceutical AB 2015-06-04 / 08:15 --------------------------------------------------------------------- Paclical received marketing authorization in Russia Uppsala, Sweden, 2015-06-04 08:15 CEST (GLOBE NEWSWIRE) -- FOURTH QUARTER February 1 - April 30, 2015 -- Consolidated Net sales amounted to TSEK 36 (20)[1] -- Operating income was TSEK -27,791 (-35,239) -- Net income after tax amounted to TSEK -29,622 (-37,790) -- Earnings per share was SEK -0.30 (-0.45) -- Comprehensive income was TSEK -29,622 (-37,790) THE FISCAL YEAR May 1, 2014 - April 30, 2015 -- Consolidated Net sales amounted to TSEK 2,070 (60) -- Operating income was TSEK -107,767 (-98,091) -- Net income after tax amounted to TSEK -117,039 (-105,112) -- Earnings per share was SEK -1.28 (-1.27) -- Comprehensive income was TSEK -117,039 (-105,112) -- Paclical received marketing authorization in Russia. EVENTS AFTER THE CLOSING DAY -- Changes in Oasmia's Board of Directors and new CEO appointed -- Authorization for the Board to make decisions on issue of new shares, warrants and convertible debt instruments CHAIRMAN OF THE BOARD COMMENTS: 'The fourth quarter was very important for Oasmia's development, as we received our first marketing authorization for Paclical. It is now approved for treatment of ovarian cancer in Russia. We have already start to prepare for the launch in the autumn this year together with our partner in Russia, Pharmasyntez. We will continue our work with the submission of an application of marketing authorization in the EU for Paclical for treatment of ovarian cancer, the clinical development of Doxophos, Doxophos Vet, Paccal Vet and Docecal, and our collaboration with Baxter for full scale commercial pharmaceutical production', commented Oasmia's chairman of the board Julian Aleksov. [1]The numbers in parentheses show the results from the corresponding period of the previous year Anders Lundin, CFO Tel: +46 70 209 63 00 E-mail: anders.lundin@oasmia.com News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-06-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden ISIN: SE0000722365 End of News DGAP News-Service --------------------------------------------------------------------- 365337 2015-06-04
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden